Radiation dosimetry of para-chloro-2-[¹⁸F]fluoroethyl-etomidate: a PET tracer for adrenocortical imaging.

IF 3.1 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

EJNMMI Research Pub Date : 2024-05-21 DOI:10.1186/s13550-024-01109-2

Isabella Silins, Adrian Moreno, Anders Wall, Franklin Aigbirhio, Mark Gurnell, Morris Brown, Sara Roslin, Gunnar Antoni, Per Hellman, Anders Sundin, Mark Lubberink

{"title":"Radiation dosimetry of para-chloro-2-[18F]fluoroethyl-etomidate: a PET tracer for adrenocortical imaging.","authors":"Isabella Silins, Adrian Moreno, Anders Wall, Franklin Aigbirhio, Mark Gurnell, Morris Brown, Sara Roslin, Gunnar Antoni, Per Hellman, Anders Sundin, Mark Lubberink","doi":"10.1186/s13550-024-01109-2","DOIUrl":null,"url":null,"abstract":"Background: [11C]metomidate, a methyl ester analogue of etomidate, is used for positron emission tomography of adrenocortical cancer, and has been tested in recent clinical trials for lateralization in primary aldosteronism (PA). However, in PA, visualization as well as uptake quantification are hampered by the tracer's rather high non-specific liver uptake, and its overall clinical usefulness is also limited by the short 20-minute half-life of carbon-11. Therefore, we evaluated para-chloro-2-[18F]fluoroethyl-etomidate, [18F]CETO, a fluorine-18 (T1/2=109.8 min) analogue, as a potential new adrenocortical PET tracer. The aim of this study was to assess radiation dosimetry of [18F]CETO.Results: [18F]CETO showed a high uptake in adrenal glands, still increasing at 5 h post injection. Adrenal glands (absorbed dose coefficients 0.100 ± 0.032 mGy/MBq in males and 0.124 ± 0.013 mGy/MBq in females) received the highest absorbed dose. The effective dose coefficient was 20 µSv/MBq.Conclusions: [18F]CETO has a favourable biodistribution in humans for adrenal imaging. The effective dose for a typical clinical PET examination with 200 MBq [18F]CETO is 4 mSv.Trial registration: ClinicalTrials.gov, NCT05361083 Retrospectively registered 29 April 2022. at, URL: https://clinicaltrials.gov/ct2/show/NCT05361083.","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"48"},"PeriodicalIF":3.1000,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11109037/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-024-01109-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: [¹¹C]metomidate, a methyl ester analogue of etomidate, is used for positron emission tomography of adrenocortical cancer, and has been tested in recent clinical trials for lateralization in primary aldosteronism (PA). However, in PA, visualization as well as uptake quantification are hampered by the tracer's rather high non-specific liver uptake, and its overall clinical usefulness is also limited by the short 20-minute half-life of carbon-11. Therefore, we evaluated para-chloro-2-[¹⁸F]fluoroethyl-etomidate, [¹⁸F]CETO, a fluorine-18 (T_1/2=109.8 min) analogue, as a potential new adrenocortical PET tracer. The aim of this study was to assess radiation dosimetry of [¹⁸F]CETO.

Results: [¹⁸F]CETO showed a high uptake in adrenal glands, still increasing at 5 h post injection. Adrenal glands (absorbed dose coefficients 0.100 ± 0.032 mGy/MBq in males and 0.124 ± 0.013 mGy/MBq in females) received the highest absorbed dose. The effective dose coefficient was 20 µSv/MBq.

Conclusions: [¹⁸F]CETO has a favourable biodistribution in humans for adrenal imaging. The effective dose for a typical clinical PET examination with 200 MBq [¹⁸F]CETO is 4 mSv.

Trial registration: ClinicalTrials.gov, NCT05361083 Retrospectively registered 29 April 2022. at, URL: https://clinicaltrials.gov/ct2/show/NCT05361083.

查看原文本刊更多论文

对氯-2-[18F]氟乙基依托咪酯：肾上腺皮质成像 PET 示踪剂的辐射剂量学。

背景：[11C]甲氧嘧啶是依托咪酯的甲酯类似物，用于肾上腺皮质癌的正电子发射断层扫描，并在最近的临床试验中用于原发性醛固酮增多症（PA）的侧位试验。然而，在原发性醛固酮增多症中，该示踪剂对肝脏的非特异性摄取相当高，这妨碍了其可视化和摄取定量，而且碳-11 20 分钟的短半衰期也限制了其总体临床用途。因此，我们评估了对氯-2-[18F]氟乙基依托咪酯，即[18F]CETO，一种氟-18（T1/2=109.8 分钟）类似物，作为一种潜在的新型肾上腺皮质 PET 示踪剂。本研究的目的是评估[18F]CETO的辐射剂量学：结果：[18F]CETO 在肾上腺中的吸收率很高，注射后 5 小时仍在增加。肾上腺的吸收剂量最高（男性吸收剂量系数为 0.100 ± 0.032 mGy/MBq，女性吸收剂量系数为 0.124 ± 0.013 mGy/MBq）。有效剂量系数为 20 µSv/MBq：结论：[18F]CETO 在人体肾上腺成像中具有良好的生物分布。使用 200 MBq [18F]CETO 进行典型临床 PET 检查的有效剂量为 4 mSv：试验注册：ClinicalTrials.gov，NCT05361083，2022 年 4 月 29 日追溯注册。网址：https://clinicaltrials.gov/ct2/show/NCT05361083。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJNMMI Research RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-

CiteScore

5.90

自引率

3.10%

发文量

审稿时长

13 weeks

期刊介绍： EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies. The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.